Your browser doesn't support javascript.
loading
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.
Bochtler, Tilmann; Reiling, Anna; Endris, Volker; Hielscher, Thomas; Volckmar, Anna-Lena; Neumann, Olaf; Kirchner, Martina; Budczies, Jan; Heukamp, Lukas C; Leichsenring, Jonas; Allgäuer, Michael; Kazdal, Daniel; Löffler, Harald; Weichert, Wilko; Schirmacher, Peter; Stenzinger, Albrecht; Krämer, Alwin.
Afiliación
  • Bochtler T; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Reiling A; Department of Thoracic Oncology, Thoraxklinik Heidelberg, Heidelberg, Germany.
  • Endris V; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Germany.
  • Hielscher T; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Volckmar AL; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Neumann O; Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
  • Kirchner M; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Budczies J; German Cancer Consortium (DKTK), Germany.
  • Heukamp LC; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Leichsenring J; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Allgäuer M; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Kazdal D; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Löffler H; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Weichert W; Institute for Haematopathology Hamburg, Hamburg, Germany.
  • Schirmacher P; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Krämer A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Int J Cancer ; 146(11): 3053-3064, 2020 06 01.
Article en En | MEDLINE | ID: mdl-31970771
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Primarias Desconocidas / Carcinoma de Células Escamosas / Adenocarcinoma / Proteínas Proto-Oncogénicas p21(ras) / Inhibidor p16 de la Quinasa Dependiente de Ciclina Tipo de estudio: Guideline / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male Idioma: En Revista: Int J Cancer Año: 2020 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Primarias Desconocidas / Carcinoma de Células Escamosas / Adenocarcinoma / Proteínas Proto-Oncogénicas p21(ras) / Inhibidor p16 de la Quinasa Dependiente de Ciclina Tipo de estudio: Guideline / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male Idioma: En Revista: Int J Cancer Año: 2020 Tipo del documento: Article País de afiliación: Alemania